Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Inovio Expands Ebola Vaccine Trial

By The Life Sciences Report, on August 24th, 2016 in Expert Interviews

Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an “optimal” strategy for intradermal (skin) vaccination.

“In the first part of the study [with 75 patients], the cohort receiving two doses via intradermal (vs. intramuscular) vaccination, 13/13 subjects produced strong anti-ebola antibody responses. The second stage of the study will evaluate number of doses, lower doses and a combination with DNA-based IL-12,” Kolbert wrote in an Aug. 11 research report.

“The intradermal approach is also being evaluated for Inovio’s Zika vaccine, now in a human study,” Kolbert wrote.

While Kolbert acknowledges that Inovio’s Ebola, Zika and MERS programs continue to make progress, “our focus remains on VGX-3100 and the start of the pivotal program, hopefully by YE16.” VGX-3100 targets cervical dysplasia.

http://jutiagroup.com/20160824-inovio-expands-ebola-vaccine-trial/